The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives

N Dookie, SL Ngema, R Perumal… - Clinical Microbiology …, 2022 - Am Soc Microbiol
Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs

MGG Sturkenboom, AG Märtson, EM Svensson… - Clinical …, 2021 - Springer
Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR …

AHXP Chan Kwong, EAM Calvier, D Fabre… - … of Pharmacokinetics and …, 2020 - Springer
Population pharmacokinetic analysis is used to estimate pharmacokinetic parameters and
their variability from concentration data. Due to data sparseness issues, available datasets …

The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs

M Wijk, K Gausi, S Malatesta, SE Weber… - Journal of …, 2024 - academic.oup.com
Abstract Background In South Africa, an estimated 11% of the population have high alcohol
use, a major risk factor for TB. Alcohol and other substance use are also associated with …

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment

R Verma, S Patil, N Zhang, FMF Moreira… - American journal of …, 2021 - atsjournals.org
Rationale: Standardized dosing of antitubercular drugs contributes to a substantial
incidence of toxicities, inadequate treatment response, and relapse, in part due to variable …

N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment

T Mthiyane, J Millard, J Adamson… - Antimicrobial agents …, 2020 - Am Soc Microbiol
The distribution of N-acetyltransferase 2 gene (NAT2) polymorphisms varies considerably
among different ethnic groups. Information on NAT2 single-nucleotide polymorphisms in the …

Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients

L Thomas, S Sekhar Miraj, M Surulivelrajan, M Varma… - Antibiotics, 2020 - mdpi.com
Rifampin (RF) is metabolized in the liver into an active metabolite 25-desacetylrifampin and
excreted almost equally via biliary and renal routes. Various influx and efflux transporters …

Machine learning approach in dosage individualization of isoniazid for tuberculosis

BH Tang, XF Zhang, SM Fu, BF Yao, W Zhang… - Clinical …, 2024 - Springer
Introduction Isoniazid is a first-line antituberculosis agent with high variability, which would
profit from individualized dosing. Concentrations of isoniazid at 2 h (C2h), as an indicator of …

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of …

L Thomas, AP Raju, Chaithra, M Varma… - European Journal of …, 2022 - Springer
Purpose Significant pharmacokinetic variabilities have been reported for isoniazid across
various populations. We aimed to summarize population pharmacokinetic studies of …

[HTML][HTML] Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure

PQ Hoa, HK Kim, TW Jang, H Seo, JY Oh… - International Journal of …, 2024 - Elsevier
Background Rifampicin (RIF) exhibits high pharmacokinetic (PK) variability among
individuals; a low plasma concentration might result in unfavorable treatment outcomes and …